The expression patterns of ER, PR, HER2, CK5/6, EGFR, KI-67 and AR by immunohistochemical analysis in breast cancer cell lines

Breast Cancer: Basic and Clinical Research

Volumn 4, Issue 1, 2010, Pages 35-41

  Subik, Kristina ^a   Lee, Jin Feng ^b   Baxter, Laurie ^a   Strzepek, Tamera ^a   Costello, Dawn ^a   Crowley, Patti ^a   Xing, Lianping ^a   Hung, Mien Chie ^b,c   Bonfiglio, Thomas ^a   Hicks, David G ^a   Tang, Ping ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Cell lines; Immunohistochemistry; Molecular classification

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL STRAIN AU 565; CELL STRAIN BT 20; CELL STRAIN BT 468; CELL STRAIN BT 474; CELL STRAIN BT 483; CELL STRAIN HBL 101; CELL STRAIN HS 598 T; CELL STRAIN MCF 10A; CELL STRAIN MCF 10F; CELL STRAIN MCF 12A; CELL STRAIN MCF 7; CELL STRAIN MDA MD 231; CELL STRAIN MDA MD 435; CELL STRAIN MDA MD 453; CELL STRAIN SKBR 3; CELL STRAIN ZR 75 1; CONTROLLED STUDY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TUMOR CELL LINE;

EID: 77953408213     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.1177/117822341000400004     Document Type: Article

References (41)

1. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol. 2005;205:248-54.
2. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol. 2007;360:91-114.
3. Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J Biol. 2008;7:6.
4. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-23.
7. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6.
8. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347: 1999-2009.
9. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
10. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basallike subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-71.
11. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492-502.
12. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30:1097-104.
13. Spitale A, Mazzola P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland. Ann Oncol. 2009;20:628-35.
14. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50.
15. Sorlie T. Introducing molecular subtyping of breast cancer into the clinic? J Clin Oncol. 2009;27:1153-4.
16. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 2009;59:303-13.
17. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis, are we ready? Diagn Mol Pathol. 2009;18:125-32.
18. Peng J, Jordan VC. Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. Int J Oncol. 2010;36:451-8.
19. Martin FT, Dwyer RM, Kelly J, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat. 2010 Jan 20 [Epub ahead of print].
20. Ye Y, Xiao Y, Wang W, et al. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene. 2010;29:1451-62. Epub 2010 Jan 18.
21. Tulchin N, Chambon M, Juan G, et al. BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. Am J Pathol. 2010; 176:1203-14. Epub 2010 Jan 14.
22. Gökmen-Polar Y, Mehta R, Tuzmen S, et al. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat. 2010 Jan 23 [Epub ahead of print].
23. Bonelli MA, Fumarola C, Alfieri RR, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Jan 7 [Epub ahead of print].
24. Pietkiewicz J, Zielinska K, Saczko J, et al. New approach to hydrophobic cyanine-type photosensitizer delivery using polymeric oil-cored nanocarriers: hemolytic activity, in vitro cytotoxicity and localization in cancer cells. Eur J Pharm Sci. 2010:39:322-35. Epub 2010 Jan 7.
25. Harvey J, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-81.
26. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45.
27. Chhieng DC, Frost AR, Niwas S, et al. Intratumor heterogeneity of biomarker expression in breast carcinomas. Biotech Histochem. 2004;79:25-36.
28. Schobesberger M, Baltzer A, Oberli A, et al. Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. BMA Cancer. 2008;8:343.
29. Liu Q, Loo WTY, Sze SCW, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by downregulation of NFkB, cyclin D and MMP-1 transcription. Phytomedicine. 2009;16:916-22.
30. Steffen AC, Gostring L, Tolmachev V, et al. Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging. 2008;35:1179-91.
31. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-26.
32. Ahlin C, Aaltonen K, Amini RM, et al. Ki-67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology. 2007;51:491-8.
33. Ogata H, Sato H, Takatsuka J, de Luca LM. Human breast cancer MDAMB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MARK and activated Ras. Cancer Lett. 2001;172:159-64.
34. Shevde LA, Welch DR. Metastasis suppressor pathways-an evolving paradigm. Cancer Lett. 2003;198:1-20.
35. Meehan WJ, Welch DR. Breast cancer metastasis suppressor 1: update. Clin Exp Metastasis. 2003;20:45-50.
36. Hicks DG, Yoder BJ, Short S, et al. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res. 2006;12:6702-8.
37. Schippinger W, Regitnig P, Dandachi N, et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch. 2006;449:24-30.
38. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007;109:25-32.
39. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas. Potential relevance to new therapeutic strategies. Cancer. 2003;98:703-11.
40. Hanley K, Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol. 2008;39:386-92.
41. Lu F, Zahid M, Wang C, et al. Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res. 2008;1:135-45.